Company Description
Imunon, Inc., a clinical-stage biotechnology company, engages in the development of immunotherapies and next-generation vaccines to treat cancer and infectious diseases.
The Company's lead clinical program IMNN-001, a DNA-based immunotherapy for the localized treatment of ovarian cancer that is in Phase II clinical development.
It also develops ThermoDox, a direct chemotherapy. In addition, the company is developing IMNN-101, a COVID-19 booster vaccine which is in preclinical trials; IMNN-102 for the of the Lassa virus which is in preclinical trials; and IMNN-201, a Trp2 tumor associated antigen cancer vaccine in melanoma.
Further, it develops non-viral DNA technology across four modalities, such as TheraPlas for the coding of proteins and cytokines in the treatment of solid tumors; PlaCCine for the coding of viral antigens that can elicit a strong immunological response; FixPlas for the application of Imunon's DNA technology to produce universal cancer vaccines; and IndiPlas, which is in the discovery phase and will focus on the development of personalized cancer vaccines, or neoepitope cancer vaccines.
The company was formerly known as Celsion Corporation and changed its name to Imunon, Inc. in September 2022.
Imunon, Inc. was founded in 1982 and is headquartered in Lawrenceville, New Jersey.
Country | United States |
Founded | 1982 |
IPO Date | Mar 5, 1985 |
Industry | Biotechnology |
Sector | Healthcare |
Employees | 33 |
CEO | Michael H. Tardugno |
Contact Details
Address: 997 Lenox Drive, Suite 100 Lawrenceville, New Jersey 08648 United States | |
Phone | (609) 896-9100 |
Website | imunon.com |
Stock Details
Ticker Symbol | IMNN |
Exchange | NASDAQ |
Fiscal Year | January - December |
Reporting Currency | USD |
CIK Code | 0000749647 |
ISIN Number | US15117N6022 |
Employer ID | 52-1256615 |
SIC Code | 2834 |
Key Executives
Name | Position |
---|---|
Michael H. Tardugno | Executive Chairman |
Jeffrey W. Church CPA | Chief Financial Officer, Executive Vice President and Corporate Secretary |
Dr. Khursheed Anwer M.B.A., Ph.D. | Executive Vice President and Chief Scientific Officer |
Timothy J. Tumminello CPA | Chief Accounting Officer and Controller |
Marianne M. Lambertson | Vice President of Communications and Investor Relations |
Dr. Sebastien Hazard M.D. | Executive Vice President and Chief Medical Officer |
Latest SEC Filings
Date | Type | Title |
---|---|---|
Apr 26, 2024 | DEF 14A | Other definitive proxy statements |
Apr 11, 2024 | 8-K | Current Report |
Apr 10, 2024 | RW | Filing |
Mar 28, 2024 | 10-K | Annual Report |
Mar 28, 2024 | 8-K | Current Report |
Mar 18, 2024 | 8-K | Current Report |
Mar 12, 2024 | 8-K | Current Report |
Feb 9, 2024 | S-1/A | [Amend] General form for registration of securities under the Securities Act of 1933 |
Jan 18, 2024 | S-1/A | [Amend] General form for registration of securities under the Securities Act of 1933 |
Dec 29, 2023 | 8-K | Current Report |